SEC Form 4 · accession 0001562180-18-004850
REGENXBIO Inc. · RGNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephen Yoo
Officer — Chief Medical Officer
Period of report
Dec 3, 2018
Accepted (ET)
Dec 6, 2018 · 4:22 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001590877
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 3, 2018 | M | 20,414 | $0.85 | A | 20,414 | D | |
| Common StockF2 | Dec 3, 2018 | S | 6,854 | $59.62 | D | 13,560 | D | |
| Common StockF3 | Dec 3, 2018 | S | 13,053 | $60.35 | D | 507 | D | |
| Common StockF4 | Dec 3, 2018 | S | 507 | $61.20 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F5 | $0.85 | Dec 3, 2018 | M | 20,414 | D | — | Nov 3, 2024 | Common Stock | 20,414 | 40,830 | D |
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan.
- F2This transaction was executed in multiple trades at prices ranging from $59.00 to $59.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $60.00 to $60.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $61.15 to $61.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5The previously granted option, representing a right to purchase a total of 247,900 shares, became exercisable as follows: 165,200 of the shares subject to the option are initial shares ("Initial Shares") and 82,700 of the shares subject to the option are contingent shares ("Contingent Shares"). 23,600 of the Initial Shares vested on October 13, 2014, 35,400 of the Initial Shares vested on October 13, 2015 and an additional 2,950 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 15% of the Contingent Shares were deemed vested as of October 13, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following October 13, 2014, with 25% of the remaining 85% of Contingent Shares having vested on October 13, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter.